Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas

Leiomyosarcoma Clinical Trial

Official title:

Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01426633
• Other study ID #: GISG-02
• Status: Completed
• Phase: Phase 1
• First received: August 29, 2011
• Last updated: December 15, 2014
• Start date: November 2011
• Est. completion date: December 2014

Study information

• Verified date: December 2014
• Source: Heidelberg University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

L-sarcomas represent about one third of all adult soft tissue sarcomas (24 % liposarcomas and 12 % leiomyosarcomas). Approval for the induction of trabectedin into the treatment armamentarium of advanced and/or metastatic soft tissue sarcomas after treatment failure with anthracyclines and/or ifosfamide depended mainly on its activity in the L-sarcomas (Garcia-Carbonero 2004, Le Cesne 2005, and Demetri 2009). Significant activity has been described for the use of gemcitabine and especially the combination of gemcitabine and docetaxel mainly in leiomyosarcomas and liposarcomas (Maki 2007). However, the combination of gemcitabine and docetaxel is associated with significant toxicity. Pulmonary toxicity and refractory peripheral oedema are the most common severe adverse events. The aim of the present phase I study will be to examine safety data of this promising treatment combination of gemcitabine and trabectedin in L-sarcomas.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with histologically confirmed L-sarcomas (leiomyosarcoma and liposarcoma)

• Measurable disease according to RECIST 1.1

• Any treatment line except adjuvant setting: evidence of primary metastatic situation or disease progression within the last 6 months (based on RECIST 1.1) in computed tomography or magnetic resonance imaging

• Any prior treatment possible

• Age >= 18 years

• WHO PS =< 1

• Effective contraception during study medication and up to 3 months from treatment discontinuation

• Signed informed consent form

Exclusion Criteria:

• Surgical intervention < 4 weeks

• Pregnancy or lactation

• Known allergic reaction to trabectedin or gemcitabine or one of their components

• The following laboratory values:

Absolute neutrophil count < 1.5 x 103/mm3 Platelets < 100.000/mm3 Hb < 9 g/dL Serum creatinine >= 2.5 mg/dl SGOT and/or SGPT and/or alkaline phosphatase and/or CPK > 2.5 x ULN Total bilirubin > 1 x ULN except in the case of Gilbert's syndrome

• Participation in another study (four weeks before and during the study)

• Prior malignancy apart from completely resected basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leiomyosarcoma
• Liposarcoma

Intervention

Drug:
• Gemcitabine + Trabectedin
Combination therapy of gemcitabine and trabectedin

Locations

Country	Name	City	State
Germany	Mannheim University Medical Center	Mannheim

Sponsors (1)

Lead Sponsor	Collaborator
Heidelberg University

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the maximum tolerated dose (MTD) of the combination of gemcitabine and trabectedin (Yondelis®) in patients with advanced and/or metastatic leiomyosarcoma and liposarcoma.		12 months	No
Secondary	To assess the recommended phase II dose (RPTD) of the combination of gemcitabine and trabectedin (Yondelis®) in patients with advanced and/or metastatic leiomyosarcoma and liposarcoma.		12 months	No